Software as a Medical Device Market Set for Rapid Growth Through 2034 as AI Innovation, Digital Health Adoption, and Regulatory Advances Reshape the Competitive Landscape

The global Software as a Medical Device (SaMD) market is projected to grow from USD 2.10 billion in 2025 to USD 8.90 billion by 2034, expanding at a CAGR of 17.4%. Growth is driven by AI-enabled diagnostics, digital therapeutics, cloud-based deployment, and maturing regulatory pathways. Diagnostic and screening software leads with 42% market share, while radiology applications dominate at 34%. North America holds 45% of the market, with Asia-Pacific expected to record the fastest growth.

09/17/2026, 6:51 AM • GlobeNewswire

Intuitive Surgical's Growth Has Cooled From Its Post-Pandemic Highs. Is That a Buying Opportunity or a Warning?

Intuitive Surgical's stock has declined 40% from recent highs amid slowing da Vinci robot sales growth due to increased competition from Medtronic and Johnson & Johnson. However, the company's core business model relies on recurring revenue from parts and services (75% of revenue), which provides stable annuity-like income streams. With valuation metrics below five-year averages and continued AI opportunities, the stock may represent a buying opportunity for aggressive growth investors despite its historical volatility.

09/05/2026, 3:15 PM • The Motley Fool

Renal Denervation Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)

The global renal denervation market is expected to experience significant growth driven by rising resistant hypertension cases, positive clinical trial results, regulatory approvals, and technological advances in radiofrequency, ultrasound, and micro-infusion technologies. North America currently leads the market while Asia-Pacific is projected to grow fastest. The minimally invasive procedure treats uncontrolled hypertension by disrupting sympathetic nerves surrounding renal arteries.

09/04/2026, 10:54 AM • GlobeNewswire

4 Reasons to Buy Medtronic Stock Like There's No Tomorrow

Medtronic, a major medical device maker, is experiencing a recovery after a 30% decline over five years. The company achieved its strongest revenue growth in a decade (8.4% in fiscal 2026), driven by cardiovascular business expansion. With improving free cash flow, a 3.1% dividend yield, and plans to become a Dividend King, Medtronic trades at a valuation discount (18x forward earnings) compared to peers and the S&P 500.

09/03/2026, 12:05 PM • The Motley Fool

Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

The global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.

08/26/2026, 7:57 AM • GlobeNewswire

Global Veterinary Medical Devices Market to Reach $9.1 Billion by 2030, Driven by Rising Pet Ownership and Technological Innovation in Animal Healthcare

The global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.

08/25/2026, 2:53 PM • GlobeNewswire

Intravascular Lithotripsy Market Size to Reach USD 4.19 Billion by 2035 as Coronary and Peripheral IVL Adoption Accelerates – SNS Insider

The global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.

08/25/2026, 11:59 AM • GlobeNewswire

Competition Is Heating Up, but Here's Why Intuitive Surgical Might Still Be the Smartest Bet in MedTech

Intuitive Surgical faces new competition from Medtronic and Johnson & Johnson in the surgical robotics space, but maintains a strong market position with 11,710 da Vinci systems in use globally. The company's real strength lies in its recurring revenue from instruments, accessories, and services (75% of revenue), rather than system sales alone. Despite a 40% stock decline and a 42x P/E ratio, the company's large installed base and annuity-like income streams provide a competitive moat that positions it favorably for growth-oriented investors.

08/08/2026, 12:15 PM • The Motley Fool

I'm Calling It: Medtronic (MDT) Will Soar 40% by the End of 2026

Medtronic's stock has declined over 30% in the past five years due to cost pressures and competitive challenges, but analyst Leo Sun believes it could rise 40% to $121 by end of 2026. The company's recent diabetes unit spinoff, business restructuring focused on higher-margin cardiovascular and neuroscience portfolios, and strong revenue growth (8.4% in fiscal 2026) position it for recovery. Trading at 18x forward earnings with a 3.3% dividend yield and potential Dividend King status next year, Medtronic could attract significant investor attention.

08/05/2026, 12:02 PM • The Motley Fool

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

Ceribell announced the appointment of Thomas West and Sharon O'Keefe to its Board of Directors. West, former CEO of Nalu Medical (acquired by Boston Scientific for $600M) and Intersect ENT (acquired by Medtronic for $1.1B), and O'Keefe, former President of University of Chicago Medical Center, bring significant commercial and health-system leadership experience. The appointments support Ceribell's expansion as its point-of-care brain monitoring platform is now deployed in over 680 U.S. hospitals.

07/29/2026, 7:00 AM • GlobeNewswire

Implicity’s Next-Generation ILR ECG Analyzer Earns FDA Clearance

Implicity announced FDA 510(k) clearance for its next-generation ILR ECG Analyzer, a cloud-based AI software that reduces false-positive alerts from implantable cardiac monitors by up to 76% while maintaining high sensitivity. The manufacturer-agnostic algorithm works with devices from Abbott, Biotronik, Boston Scientific, and Medtronic, addressing a significant clinical workflow burden in remote cardiac monitoring.

07/28/2026, 7:45 AM • GlobeNewswire

Ultrasonic Aspirator Market Size Projected to Reach USD 376.32 Million by 2035 | SNS Insider

The global ultrasonic aspirator market is valued at USD 194.03 million in 2025 and is projected to reach USD 376.32 million by 2035, growing at a CAGR of 6.87%. The U.S. market is expected to grow from USD 67.49 million to USD 118.90 million by 2035, driven by increasing adoption of advanced surgical technologies, rising neurosurgery procedures, and growing demand for minimally invasive surgeries. North America leads the market with 39.80% share, while Asia-Pacific registers the fastest growth at 8.83% CAGR.

07/28/2026, 6:49 AM • GlobeNewswire

Electrosurgery Market Projected to Reach $11.59 Billion by 2031 as Demand for Minimally Invasive Procedures Rises - Analysis by Product, Surgery, End User and Region

The global electrosurgery market is projected to grow from $8.01 billion in 2025 to $11.59 billion by 2031, with a CAGR of 6.4%. Growth is driven by increasing surgical volumes, rising chronic disease prevalence, and adoption of minimally invasive procedures. However, challenges include procedural risks, regulatory constraints, and surgeon shortages. Ambulatory surgical centers are expanding their role, while the United States leads North American growth.

07/24/2026, 10:41 AM • GlobeNewswire

[Latest] Global Implantable Cardiac Fluorine-Free Resins Market Size/Share Worth USD 4.26 Billion by 2035 at a 10.8% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate,SWOT Analysis)

The global implantable cardiac fluorine-free resins market is valued at USD 1.52 billion in 2025 and is expected to grow to USD 4.26 billion by 2035 at a CAGR of 10.8%. Growth is driven by increasing cardiovascular disease prevalence, aging demographics, demand for biocompatible materials, and advancements in manufacturing technologies like additive manufacturing. Asia Pacific is projected to experience the fastest growth, while North America and Europe maintain steady expansion.

07/23/2026, 4:30 AM • GlobeNewswire

Global Robotic Endoscopy Devices Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~10% by 2034 | DelveInsight

The global robotic endoscopy devices market is projected to grow from USD 2.8 billion in 2025 to USD 6.5 billion by 2034, driven by increasing demand for minimally invasive procedures, technological advancements in AI-enabled navigation and imaging, and rising prevalence of gastrointestinal disorders. North America leads the market with 42% share, while Asia-Pacific is expected to witness the highest growth. Key players include Intuitive Surgical, Medtronic, Johnson & Johnson MedTech, and others.

07/22/2026, 1:00 PM • GlobeNewswire